0000000000759697

AUTHOR

Hermann E. Wasmuth

showing 2 related works from this author

Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer

2012

Background Hepatocellular carcinoma (HCC) is a typical inflammation-associated cancer, but may also provoke antitumour immune responses whose significance and underlying mechanisms are incompletely understood. Objective To characterise immune responses in the diethylnitrosamine (DEN)-liver cancer mouse model. Design Tumour development and immune cell functions upon DEN treatment were compared between C57BL/6 wild-type (WT), chemokine scavenging receptor D6-deficient, B cell- (Igh6), CD4 T cell- (MHC-II) and T-/B cell-deficient (Rag1) mice. Relevance for human HCC was tested by comparing gene array results from 139 HCC tissues. Results The induction of premalignant lesions after 24 weeks and…

MalePathologymedicine.medical_specialtyCarcinoma HepatocellularAdaptive ImmunityBiologyMajor histocompatibility complexChemokine CXCL9ArticleCCL5MiceLiver Neoplasms ExperimentalImmune systemAntigenLeukocytesmedicineAnimalsHumansCytotoxic T cellDiethylnitrosamineChemokine CCL5Chemokine CCL2B cellOligonucleotide Array Sequence AnalysisMice KnockoutB-LymphocytesMacrophagesLiver NeoplasmsGastroenterologyAcquired immune systemSurvival Analysisdigestive system diseasesMice Inbred C57BLmedicine.anatomical_structureCarcinogensDisease ProgressionCancer researchbiology.proteinPrecancerous ConditionsBiomarkersCD8T-Lymphocytes CytotoxicGut
researchProduct

Long-Term Efficacy of Tenofovir Monotherapy for Hepatitis B Virus-Monoinfected Patients After Failure of Nucleoside/Nucleotide Analogues

2010

Tenofovir disoproxil fumarate (TDF) has demonstrated high antiviral efficacy in treatment-naive patients with chronic hepatitis B virus (HBV) infection but experience in nucleoside/nucleotide analogue (NA)-experienced patients is limited. In this retrospective multicenter study we therefore assessed the long-term efficacy of TDF monotherapy in patients with prior failure or resistance to different NA treatments. Criteria for inclusion were HBV DNA levels >4.0 log(10) copies/mL at the start and a minimum, period of TDF therapy for at least 6 months. In all, 131 patients (mean age 42 +/- 12 years, 95 male, 65% hepatitis B e antigen [HBeAg]-positive) were eligible. Pretreatment consisted of…

AdultMalemedicine.medical_specialtyHBsAgAdolescentOrganophosphonatesPharmacologyBiologymedicine.disease_causeGastroenterologyCohort StudiesSDG 3 - Good Health and Well-beingInternal medicineDrug Resistance ViralmedicineAdefovirHumansHepatitis B e AntigensTenofovirRetrospective StudiesHepatitis B virusHepatitis B Surface AntigensHepatologyReverse-transcriptase inhibitorAdenineLamivudinevirus diseasesEntecavirHepatitis BMiddle Agedmedicine.diseaseHepatitis BTreatment OutcomeHBeAgLamivudineFemalemedicine.drugHepatology
researchProduct